Managing Atrial Fibrillation

Structures AF management with CHA2DS2-VASc scoring, anticoagulation selection, and rate/rhythm control strategies.

Why This Skill Exists

Atrial fibrillation (AF) affects 6 million Americans and is associated with a five-fold increase in stroke risk. The cornerstone of AF management is appropriate anticoagulation stratified by thromboembolic risk, combined with a rate- or rhythm-control strategy tailored to symptoms and comorbidities. The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation introduced significant changes, including reclassification of AF types and earlier rhythm-control recommendations.

Failure to properly risk-stratify with CHA2DS2-VASc, initiate appropriate anticoagulation, or select the correct rate/rhythm strategy leads to preventable strokes, bleeding complications, and tachycardia-mediated cardiomyopathy.

Checkpoint A: Pre-Draft Intake (Mandatory)

What type of AF is this — paroxysmal, persistent, long-standing persistent, or permanent? (default: "AF type not classified")
When was AF first diagnosed? Is this new-onset? (default: "Duration unknown")
What are the CHA2DS2-VASc components — CHF, HTN, age, diabetes, prior stroke/TIA, vascular disease, sex? (default: "Score not calculated")
Is the patient currently on anticoagulation? If so, which agent and dose? (default: "Anticoagulation status unknown")
Has bleeding risk been assessed (HAS-BLED score)? (default: "Not calculated")
What is the current ventricular rate and is the patient symptomatic? (default: "Rate and symptoms not documented")
Is there a history of cardioversion, ablation, or left atrial appendage closure? (default: "No prior rhythm procedures")
What is the LVEF — is there tachycardia-mediated cardiomyopathy concern? (default: "LVEF not documented")

Documents to Request

12-lead ECG confirming AF or recent Holter/event monitor
Echocardiogram (LA size, LVEF, valve disease)
Current medication list
Recent labs: CBC, BMP, TSH, INR (if on warfarin), hepatic function
Prior cardioversion or ablation procedure notes
Bleeding history and any contraindications to anticoagulation
CHA2DS2-VASc and HAS-BLED component documentation

Step 1: AF Classification and CHA2DS2-VASc Scoring

2023 AF Classification: | Type | Definition | |------|-----------| | Paroxysmal | Terminates spontaneously or with intervention within 7 days | | Persistent | Continuous AF lasting > 7 days | | Long-standing persistent | Continuous AF > 12 months when rhythm control is pursued | | Permanent | AF accepted; no further rhythm-control attempts |

CHA2DS2-VASc Score Calculation:

| Risk Factor | Points | |-------------|--------| | Congestive heart failure | 1 | | Hypertension | 1 | | Age ≥ 75 | 2 | | Diabetes mellitus | 1 | | Stroke/TIA/thromboembolism | 2 | | Vascular disease (prior MI, PAD, aortic plaque) | 1 | | Age 65–74 | 1 | | Sex category (female) | 1 |

Anticoagulation Decision: | CHA2DS2-VASc (Male) | CHA2DS2-VASc (Female) | Recommendation | |---------------------|----------------------|----------------| | 0 | 1 (sex factor only) | No anticoagulation | | 1 | 2 | Consider anticoagulation (Class IIa) | | ≥ 2 | ≥ 3 | Anticoagulation recommended (Class I) |

Step 2: Anticoagulation Selection

DOACs (preferred over warfarin per 2023 guidelines):

| Agent | Dose (CrCl ≥ 50) | Reduced Dose | Dose Reduction Criteria | |-------|-------------------|-------------|------------------------| | Apixaban | 5 mg BID | 2.5 mg BID | ≥ 2 of: age ≥ 80, weight ≤ 60 kg, Cr ≥ 1.5 | | Rivaroxaban | 20 mg daily with food | 15 mg daily | CrCl 15–50 mL/min | | Dabigatran | 150 mg BID | 75 mg BID | CrCl 15–30 mL/min | | Edoxaban | 60 mg daily | 30 mg daily | CrCl 15–50, weight ≤ 60 kg, or P-gp inhibitor |

Warfarin Indications (when DOACs are contraindicated):

Mechanical heart valve
Moderate-to-severe mitral stenosis
CrCl < 15 mL/min (or dialysis) — though apixaban has data in ESRD
Antiphospholipid syndrome
Target INR 2.0–3.0; TTR goal > 70%

HAS-BLED Score (Bleeding Risk Assessment):

Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly (> 65), Drugs/alcohol
Score ≥ 3 = high bleeding risk → does NOT contraindicate anticoagulation; rather, mandates closer monitoring and modifiable risk factor correction

Step 3: Rate Control Strategy

Target: Resting HR < 110 bpm (lenient) or < 80 bpm (strict if symptomatic)

First-line Agents:

| Agent | Dose Range | Contraindications | |-------|-----------|-------------------| | Metoprolol succinate | 25–200 mg daily | Decompensated HF, severe bradycardia | | Diltiazem | 120–360 mg daily (ER) | HFrEF (LVEF ≤ 40%), severe bradycardia | | Verapamil | 120–360 mg daily (ER) | HFrEF, concurrent BB use | | Digoxin | 0.125–0.25 mg daily | Renal impairment (adjust), hypokalemia |

In HFrEF: beta-blockers preferred; avoid CCBs. Digoxin may be added if beta-blocker insufficient.
Amiodarone for rate control only as last resort (toxicity profile).
AV node ablation + pacemaker for refractory rate control in permanent AF.

Step 4: Rhythm Control Strategy

2023 Guideline Shift — Earlier Rhythm Control: The EAST-AFNET 4 trial demonstrated that early rhythm control (within 12 months of diagnosis) reduces cardiovascular death, stroke, and hospitalization compared to rate control alone.

Antiarrhythmic Drug Selection:

| Agent | Structural Heart Disease | Key Toxicity | |-------|------------------------|-------------| | Flecainide | Contraindicated with CAD or HFrEF | Proarrhythmic; requires AV nodal blocking agent | | Propafenone | Contraindicated with CAD or HFrEF | Proarrhythmic | | Sotalol | Use with caution in HFrEF | QT prolongation; initiate in hospital | | Dofetilide | Safe in HFrEF | QT prolongation; 3-day in-hospital initiation | | Amiodarone | Safe in all structural disease | Thyroid, pulmonary, hepatic, ocular toxicity | | Dronedarone | Contraindicated in HFrEF and permanent AF | Hepatotoxicity; less effective than amiodarone |

Catheter Ablation (Class I for symptomatic AF refractory to ≥ 1 AAD):

Pulmonary vein isolation (PVI) is the cornerstone technique
CASTLE-AF: ablation in HFrEF reduces mortality and HF hospitalization
May be considered first-line in selected patients (Class IIa)

Cardioversion Protocol:

If AF duration > 48 hours or unknown: 3 weeks anticoagulation pre-cardioversion OR TEE to exclude LAA thrombus
4 weeks anticoagulation post-cardioversion minimum; long-term based on CHA2DS2-VASc

Step 5: Special Populations and Monitoring

Post-operative AF: May be self-limited; short-term rate control and anticoagulation for 30–60 days. AF with WPW: Avoid AV nodal blockers (digoxin, CCBs, adenosine); use procainamide or ibutilide. AF with RVR causing hemodynamic instability: Emergent synchronized cardioversion.

Ongoing Monitoring:

Symptom assessment using EHRA score at each visit
Annual TFTs and LFTs if on amiodarone; CXR and PFTs every 6–12 months
Renal function monitoring for DOAC dose adjustments (annually or more if declining)
LA size surveillance on echo — progressive dilation suggests inadequate rhythm control

Checkpoint B: Post-Draft Alignment (Mandatory)

Is the CHA2DS2-VASc score calculated with all components documented?
Is the anticoagulation decision aligned with the score and documented?
Is the rate vs. rhythm control strategy explicitly justified?
Are antiarrhythmic drug contraindications checked against cardiac structure?
Is a cardioversion/ablation plan included or deferred with rationale?

Quality Audit

[ ] AF type classified per 2023 guidelines
[ ] CHA2DS2-VASc score calculated with individual components listed
[ ] Anticoagulation initiated, deferred, or contraindicated with documentation
[ ] DOAC selected with appropriate dose and renal adjustment
[ ] HAS-BLED calculated and modifiable risk factors addressed
[ ] Rate control target and agent documented
[ ] Rhythm control considered with AAD selection or ablation referral
[ ] Structural heart disease assessed before AAD selection
[ ] Cardioversion anticoagulation protocol followed if applicable
[ ] LVEF assessed for tachycardia-mediated cardiomyopathy
[ ] Thyroid function checked (AF can be caused by hyperthyroidism)
[ ] Follow-up plan includes symptom, rate, and anticoagulation monitoring
[ ] Left atrial appendage occlusion considered if anticoagulation contraindicated

Guidelines

DOACs are preferred over warfarin for non-valvular AF in all patients without mechanical valves or moderate-to-severe mitral stenosis.
A CHA2DS2-VASc score of 0 in males (1 in females from sex factor alone) means no anticoagulation — do not overtreat.
High HAS-BLED score is not a reason to withhold anticoagulation — it is a prompt to address modifiable bleeding risk factors.
Never use flecainide or propafenone in patients with structural heart disease, prior MI, or HFrEF — proarrhythmic risk is prohibitive.
Amiodarone is the most effective AAD but has cumulative toxicity — reserve for patients who cannot tolerate or have failed other agents.
Early rhythm control (within 12 months of AF diagnosis) is now supported by trial evidence and should be offered to symptomatic patients.
Anticoagulation decisions should be independent of the rate vs. rhythm strategy — stroke risk persists regardless of rhythm control success.
Always document the clinical rationale for choosing rate control over rhythm control or vice versa.